देश: इंडोनेशिया
भाषा: इंडोनेशियाई
स्रोत: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency
MOXIFLOXACIN HYDROCHLORIDE
BAYER INDONESIA - Indonesia
MOXIFLOXACIN HYDROCHLORIDE
436.8 MG
TABLET SALUT SELAPUT
DUS, 20 DUS @ 7 BLISTER @ 5 TABLET SALUT SELAPUT (BULK)
BAYER HEALTHCARE MANUFACTURING S.R.L - Italy
2021-10-18
AVELOX ® ANTIBACTERIAL FILM-COATED TABLET Important information, please read carefully! COMPOSITION Avelox 400mg film coated-tablets: 1 film-coated tablet contains 400 mg moxifloxacin (as hydrochloride). PROPERTIES PHARMACOLOGICAL PROPERTIES PHARMACODYNAMYC PROPERTIES PHARMACOTHERAPEUTIC GROUP: Quinolone antibacterials, fluoroquinolones ATC CODE: J01MA 14 Moxifloxacin is a fluoroquinolone antibacterial. MECHANISM OF ACTION _In vitro, _ moxifloxacin has been shown to have activity against a wide range of Gram-positive and Gram-negative pathogens. The bacterial action results from the interference with topoisomerase II (DNA Gyrase) and IV. Topoisomerases are essential enzymes which play a crucial part in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is also known to influence bacterial chromosome division. Kinetic investigations have demonstrated that moxifloxacin exhibits a concentration dependent killing rate. Minimum bacterial concentrations (MBC) were found to be the range of the minimum inhibitory concentration (MIC). INTERFERENCE WITH CULTURE TEST Moxifloxacin therapy may give false negative culture results for _ Mycobacterium spp_. By suppression of mycobacterial growth. Effect on the intestinal flora in humans The following changes in the intestinal flora were seen in volunteers following administration of moxifloxacin: _ E. coli, _ _Bacillus _ _spp_., _Enterococci,_ and _Klebsiella _ _spp. _ were reduced, as were the anaerobes _Bacteroides _ _vulgatus, _ _Bifidobacterium_, _Eubacterium_, and _Peptostreptococcus_. For _B. fragilis_ there was an increase. These changes returned to normal within two weeks. There was no selection of _ Clostridium difficile _ (MIC 90 2 mg/l) and its toxin under the administration of moxifloxacin. Moxifloxacin is no t indicated for the treatment of _Clostridium difficile_. The prevalence of resistance may vary geographically and with time for selected species and local area i n fo rmati o n o n resistance is desirable, particularly when treating s पूरा दस्तावेज़ पढ़ें